Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: A phase i clinical trial

Ophthalmology

Volumn 118, Issue 1, 2011, Pages 111-118

  Heier, Jeffrey S ^a   Brown, David ^b   Ciulla, Thomas ^c   Abraham, Prema ^d   Bankert, Joy M ^a   Chong, Sandy ^a   Daniel Jr , Paul E ^a   Kim, Ivana K ^e  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^b Vitreoretinal Consultants   (United States)

^c MIDWEST EYE INSTITUTE   (United States)

^d Black Hills Regional Eye Institute   (United States)

^e MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; RANIBIZUMAB;

ADULT; ANGIOID STREAK; ARTICLE; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; DRUG EFFICACY; DRUG SAFETY; EYE PAIN; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MULTICENTER STUDY; MYOPIA; OCULAR HISTOPLASMOSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VITREOUS FLOATERS;

ADULT; ANGIOGENESIS INHIBITORS; ANGIOID STREAKS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HISTOPLASMOSIS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 78650837985     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.04.016     Document Type: Article

References (19)

1. K.B. Freund, L.A. Yannuzzi, and J.A. Sorenson Age-related macular degeneration and choroidal neovascularization Am J Ophthalmol 115 1993 786 791
2. J.Z. Cui, H. Kimura, and C. Spee Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate Graefes Arch Clin Exp Ophthalmol 238 2000 326 333
3. T. Ishibashi, Y. Hata, and H. Yoshikawa Expression of vascular endothelial growth factor in experimental choroidal neovascularization Graefes Arch Clin Exp Ophthalmol 235 1997 159 167
4. G. Martin, G. Schlunck, L.L. Hansen, and H.T. Agostini Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium Graefes Arch Clin Exp Ophthalmol 242 2004 321 326
5. Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
6. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration Ophthalmology 113 2006 1508 1521
7. D.M. Brown, M. Michels, and P.K. Kaiser Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 2009 57 65
8. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
9. Verteporfin in Photodynamic Therapy (VIP) Study Group Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3 Ophthalmology 110 2003 667 673
10. Submacular Surgery Trials Research Group Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST report no. 9 Arch Ophthalmol 122 2004 1597 1611
11. Macular Photocoagulation Study Group Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials Arch Ophthalmol 109 1991 1109 1114
12. J.M. Mones, L. Amselem, and A. Serrano Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results Eye 23 2009 1275 1280 (Lond)
13. T.Y. Lai, W.M. Chan, D.T. Liu, and D.S. Lam Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia Retina 29 2009 750 756
14. L. Konstantinidis, I. Mantel, and J.A. Pournaras Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization Graefes Arch Clin Exp Ophthalmol 247 2009 311 318
15. J.M. Ruiz-Moreno, J.A. Montero, F. Gomez-Ulla, and S. Ares Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome Br J Ophthalmol 93 2009 448 451
16. T.W. Wiegand, A.H. Rogers, and F. McCabe Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks Br J Ophthalmol 93 2009 47 51
17. Q.D. Nguyen, S.M. Shah, and G. Hafiz Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration Am J Ophthalmol 145 2008 257 266
18. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1 Am J Ophthalmol 145 2008 239 248
19. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583